Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia
ConclusionA lower CGI-S total score at baseline and greater reductions in PANSS and CGI-S scores at week 13 were associated with patients achieving disease stabilization, that may allow for a successful transition. Evidence from this study indicates that better disease condition at baseline, early functional improvement and symptomatic relief were the key factors associated with disease stabilization. The findings may guide clinicians to identify suitable patients for transition from PP1M to PP3M and further optimize the use of PP3M in China.Clinical Trials RegistrationEudraCT number: 2011-004889-15 and ClinicalTrials.gov ...
Source: CNS Drugs - January 8, 2024 Category: Neurology Source Type: research
Effect of Levetiracetam on Cognition: A Systematic Review and Meta-analysis of Double-Blind Randomized Placebo-Controlled Trials
ConclusionsThis exploratory study suggests that levetiracetam might improve executive function in specific populations. However, the diversity in study populations and potential publication bias warrant caution. (Source: CNS Drugs)
Source: CNS Drugs - December 15, 2023 Category: Neurology Source Type: research
Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia
The objective of this narrative review was to synthesize important studies, including Mendelian randomization (MR) analyses that have integrated genome-wide association studies (GWAS), as well as results from in vitro models, in vivo models, and observational studies of patients with schizophrenia. Both GWAS and MR studi es have found that schizophrenia and T2D/insulin resistance share genetic risk factors, and this may mediate a connection between peripheral or brain insulin resistance and T2D with cognition impairment and an increased risk of developing prediabetes and T2D in schizophrenia. Moreover, accumulating evidenc...
Source: CNS Drugs - December 14, 2023 Category: Neurology Source Type: research
Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies
ConclusionsThese studies demonstrate that BI 1358894 is well tolerated in healthy male volunteers following single and multiple doses, with no dose dependency observed in DRAE frequency. BI 1358894 exposure increased dose dependently in both the SAD and MAD studies, with higher exposure of BI 1358894 observed in the fed state.ClinicalTrials RegistrationThese trials have been registered on ClinicalTrials.gov: NCT03210272/1402-0001 (registered on 6 July 2017) and NCT03754959/1402-0002 (registered on 27 November 2018). (Source: CNS Drugs)
Source: CNS Drugs - November 29, 2023 Category: Neurology Source Type: research
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males
ConclusionsOverall, BI 1358894 reduced psychological and physiological responses to CCK-4 compared with placebo, as measured by PSS, subjective EVAS and objectively measured stress biomarkers. BI 1358894 had a positive safety profile, and single oral doses were well tolerated by the healthy volunteers. This trial (NCT03904576/1402-0005) was registered on Clinicaltrials.gov on 05.04.19. (Source: CNS Drugs)
Source: CNS Drugs - November 29, 2023 Category: Neurology Source Type: research
Thrombolysis with Recombinant Human Prourokinase 4.5 –6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial
ConclusionIn the 4.5 –6 h time window, more than 60% of patients at either dose of rhPro-UK (50 mg or 35 mg) achieved functional independence at 90 days without increased mortality and sICH risk. Thus, intravenous rhPro-UK was effective and safe for patients with AIS within 4.5–6 h after stroke onset. While no signi ficant differences were identified between different dosages of rhPro-UK regarding clinical outcomes, it is a logical step to further test the safety and efficacy of the low dose of rhPro-UK in a well-powered phase III study.Trial Registrationhttp://www.chictr.org.cn. Identifier: ChiCTR1800016519. Date of r...
Source: CNS Drugs - November 29, 2023 Category: Neurology Source Type: research
The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review
ConclusionOur findings are consistent with our previous work, which indicated classical psychedelics, primarily serotonin 2A receptor agonists, enhanced reward responsiveness in healthy individuals and patient populations. Lysergic acid diethylamide exhibits a unique profile in the reward learning and valuation constructs. Using the RDoC-based framework, we identified areas for future research, enhancing our understanding of the impact of LSD on reward processing. However, applying RDoC to psychedelic research faces limitations due to diverse study designs that were not initially RDoC-oriented. Limitations include subjecti...
Source: CNS Drugs - November 24, 2023 Category: Neurology Source Type: research
Context is a Critical for Psychoactive Drug Effects
(Source: CNS Drugs)
Source: CNS Drugs - November 24, 2023 Category: Neurology Source Type: research
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study
ConclusionsThis study provides evidence for the real-world effectiveness of fremanezumab in treating both high-frequency episodic migraine and chronic migraine, with meaningful and sustained improvements in multiple migraine-related variables. No new safety issue was identified. (Source: CNS Drugs)
Source: CNS Drugs - November 24, 2023 Category: Neurology Source Type: research
Levetiracetam Interaction with Direct Oral Anticoagulants: A Pharmacovigilance Study
ConclusionsOur study shows a strong signal for the levetiracetam interaction with the DOACs. Our findings suggest implementation of a drug monitoring strategy. (Source: CNS Drugs)
Source: CNS Drugs - November 22, 2023 Category: Neurology Source Type: research
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012 –2021) from a University Hospital in Germany
ConclusionMidazolam has become the preferred benzodiazepine in pre- and in-hospital settings, both in children and adults. The same applies to the increased use of levetiracetam and lacosamide over time in children and adults, while phenobarbital, phenytoin, and valproate use decreased. Continuous midazolam infusion and propofol remain the most frequently used anesthetic drugs. Mortality and outcome remain stable despite changes in medication patterns. (Source: CNS Drugs)
Source: CNS Drugs - November 18, 2023 Category: Neurology Source Type: research
Current Insights into Diagnosing and Treating Neurotuberculosis in Adults
AbstractNeurotuberculosis has the highest morbidity and mortality risk of all forms of extrapulmonary tuberculosis (TB). Early treatment is paramount, but establishing diagnosis are challenging in all three forms of neurotuberculosis: tuberculous meningitis (TBM), spinal TB and tuberculomas. Despite advancements in diagnostic tools and ongoing research aimed at improving TB treatment regimens, the mortality rate for neurotuberculosis remains high. While antituberculosis drugs were discovered in the 1940s, TB treatment regimens were designed for and studied in pulmonary TB and remained largely unchanged for decades. However...
Source: CNS Drugs - November 17, 2023 Category: Neurology Source Type: research
Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson ’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
ConclusionsEvidence suggests that novel monoamine oxidase-B inhibitors not only improve motor symptoms but also enhance patients ’ quality of life. The meta-analysis showed that both medications have a similar safety profile to placebo with regard to serious adverse events. The overall findings emphasize the effectiveness of safinamide and zonisamide in the treatment of Parkinson’s disease as adjunct therapy. Further long -term studies examining the impact of these medications on motor and non-motor symptoms are necessary. (Source: CNS Drugs)
Source: CNS Drugs - November 16, 2023 Category: Neurology Source Type: research
A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance
ConclusionsThese findings suggest that prescribed medical cannabis may have minimal acute impact on cognitive function among patients with chronic health conditions, although larger and controlled trials are needed. (Source: CNS Drugs)
Source: CNS Drugs - November 9, 2023 Category: Neurology Source Type: research
A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal-Onset Epilepsy
ConclusionNeither osteodensitometry nor bone metabolism parameters showed significant group effects after 1 year of treatment with ESL. Individual fluctuations were observed, however, which may warrant monitoring for longer follow-up periods.The study was registered in the German register for clinical studies under the number DRKS00010430 with the official name BONAPARTE. (Source: CNS Drugs)
Source: CNS Drugs - November 3, 2023 Category: Neurology Source Type: research
